Navigation Links
TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Date:5/14/2009

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

The current clinical trial is being conducted at six centers in the USA. The study enrolled 28 patients in the dose-escalation phase (completed in February 2009) and 31 patients in the dose-confirmation phase of the study (currently in progress). Primary goals of this open-label study included identification of a maximum tolerated dose (MTD) in the dose-escalation phase and accumulation of safety data, assessments of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints in both phases of the study. Preliminary trial data presented at the 2008 ASH conference indicated that the drug was well tolerated and exhibited dose-dependant reductions of splenomegaly and leukocytosis. Updated clinical data pertaining to this trial are scheduled for presentation at the European Hematology Association (EHA) conference on June 6, 2009 in Berlin.

www.targegen.com

About TargeGen, Inc.

TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors for applications in oncology and inflammatory diseases.


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
4. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
5. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Tris Pharma Announces Acceptance of Its First Two NDAs
8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
9. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
10. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
11. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... July 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... ended June 30, 2017.  The Company reported second quarter ... over the prior year period, and an increase of ... basis points of contribution from the LDR Holding Corporation ... second quarter of 2016, or 0.3% on a constant ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/25/2017)... Spain and CAMBRIDGE, Massachusetts , ... Biotech, specializing in repurposing drugs to treat rare nervous system ... Inc. to clinically develop and market the drug SOM0226 against ... the drug achieved very promising results in a Phase 2 ... A new office in the United States ...
Breaking Medicine Technology:
(Date:8/17/2017)... , ... August 17, 2017 , ... ... (ER) on Wednesday, August 16, to community partners. The newly renovated ER was ... Track” area for minor emergencies, eight semi-private rooms to deliver patient results, improve ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, ... trauma, to encourage inner healing of memories and achieve forgiveness, through a progressive ...
(Date:8/17/2017)... ... ... digital marketing for medical practices, has been recognized as one of the fastest growing privately ... second time in two years. Shawn Miele, Chief Executive Officer of Advice Media, said, “We ... a row. It’s extremely difficult to make this list once. The fact that we made ...
(Date:8/16/2017)... ... ... Summer days spent with family are priceless. Since August is Family Fun ... the season of sunshine. Add trying something new to this summer’s bucket list. Whether ... the fun. , Try Something New , Choose an activity the ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Ten outstanding teachers ... Stars in the Classroom and will win a visit by a Houston Texans player, ... who are at least five years old can visit texanschecking.com/stars to nominate their favorite ...
Breaking Medicine News(10 mins):